Search research articles
Contact Us
Filters
Showing results (491-500 of 584) with videos related to
Page
of 59
Sort By:
The Lancet. Haematology
|
September 12, 2024
Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial
Claire N Harrison, Ruben Mesa, Moshe Talpaz, et al.
Nature Genetics
|
January 17, 2024
Inherited polygenic effects on common hematological traits influence clonal selection on JAK2<sup>V617F</sup> and the development of myeloproliferative neoplasms
Jing Guo, Klaudia Walter, Pedro M Quiros, et al.
Leukemia
|
January 12, 2023
Correction: Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients
Hosuk Ryou, Korsuk Sirinukunwattana, Alan Aberdeen, et al.
British Journal of Haematology
|
December 4, 2025
Investigation and management of thrombocytosis without JAK2, CALR or MPL mutations: A British Society for Haematology Guideline
Anna L Godfrey, Alesia A Khan, Andrew McGregor, et al.
Leukemia & Lymphoma
|
June 5, 2024
Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial
Vikas Gupta, Abdulraheem Yacoub, Ruben A Mesa, et al.
Leukemia
|
December 5, 2022
Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients
Hosuk Ryou, Korsuk Sirinukunwattana, Alan Aberdeen, et al.
The Lancet. Haematology
|
June 13, 2017
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
Claire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
The New England Journal of Medicine
|
February 3, 2007
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
Linda M Scott, Wei Tong, Ross L Levine, et al.
Journal of Cachexia, Sarcopenia and Muscle
|
October 18, 2021
Effects and tolerability of exercise therapy modality on cardiorespiratory fitness in lung cancer: a randomized controlled trial
Jessica M Scott, Samantha M Thomas, James E Herndon, et al.
Haematologica
|
December 5, 2015
STAT1 activation in association with JAK2 exon 12 mutations
Anna L Godfrey, Edwin Chen, Charles E Massie, et al.
Page
of 59
Search research articles
Search
Showing results (491-500 of 584) with videos related to
Sort By:
Page
of 59
The Lancet. Haematology
|
September 12, 2024
Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial
Claire N Harrison, Ruben Mesa, Moshe Talpaz, et al.
Nature Genetics
|
January 17, 2024
Inherited polygenic effects on common hematological traits influence clonal selection on JAK2<sup>V617F</sup> and the development of myeloproliferative neoplasms
Jing Guo, Klaudia Walter, Pedro M Quiros, et al.
Leukemia
|
January 12, 2023
Correction: Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients
Hosuk Ryou, Korsuk Sirinukunwattana, Alan Aberdeen, et al.
British Journal of Haematology
|
December 4, 2025
Investigation and management of thrombocytosis without JAK2, CALR or MPL mutations: A British Society for Haematology Guideline
Anna L Godfrey, Alesia A Khan, Andrew McGregor, et al.
Leukemia & Lymphoma
|
June 5, 2024
Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial
Vikas Gupta, Abdulraheem Yacoub, Ruben A Mesa, et al.
Leukemia
|
December 5, 2022
Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients
Hosuk Ryou, Korsuk Sirinukunwattana, Alan Aberdeen, et al.
The Lancet. Haematology
|
June 13, 2017
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
Claire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
The New England Journal of Medicine
|
February 3, 2007
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
Linda M Scott, Wei Tong, Ross L Levine, et al.
Journal of Cachexia, Sarcopenia and Muscle
|
October 18, 2021
Effects and tolerability of exercise therapy modality on cardiorespiratory fitness in lung cancer: a randomized controlled trial
Jessica M Scott, Samantha M Thomas, James E Herndon, et al.
Haematologica
|
December 5, 2015
STAT1 activation in association with JAK2 exon 12 mutations
Anna L Godfrey, Edwin Chen, Charles E Massie, et al.
Page
of 59